E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Hemophilia A is a genetic disorder that impairs the body's ability to control blood clotting or coagulation, which is used to stop bleeding. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10060613 |
E.1.2 | Term | Hemophilia A (Factor VIII) |
E.1.2 | System Organ Class | 100000011915 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10053751 |
E.1.2 | Term | Hemophilia A with anti factor VIII |
E.1.2 | System Organ Class | 100000011928 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the study is to describe the time to tolerance with rFVIIIFc in subjects within a maximum of 12 months ITI treatment. |
|
E.2.2 | Secondary objectives of the trial |
•To describe the outcome of ITI treatment
•To describe the relapse rate over the 48-week period following successful ITI performed with rFVIIIFc
•To describe the intercurrent bleeding during ITI and during the 48-week period after successful ITI performed with rFVIIIFc
•To describe safety and tolerability of rFVIIIFc when used for ITI
•To evaluate the impact of ITI treatment with rFVIIIFc on health economics and adherence
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1.Ability of the subject or his legally authorized representative (e.g., parent or legal guardian) to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information in accordance with national and local subject privacy regulations.
2.Male subjects of any age diagnosed with severe hemophilia A (as confirmed from the medical record).
3.Diagnosed with high titer inhibitors (historical peak ≥5 BU/mL, according to medical records)
4.Previously treated with any plasma-derived or recombinant conventional or Extended Half-Life FVIII. |
|
E.4 | Principal exclusion criteria |
1. Other coagulation disorder(s) in addition to hemophilia A.
2. Previous ITI
3. History of hypersensitivity or anaphylaxis associated with any rFVIIIFc administration.
4. Planned major surgery to be deferred after study completion (minor surgery such as tooth extraction or insertion-replacement of central venous access device is allowed)
5. Abnormal renal function (serum creatinine >2.0 mg/dL) as assessed by local laboratory.
6. Serum alanine aminotransferase or aspartate aminotransferase >5 × upper limit of normal (ULN) as assessed by local laboratory.
7. Serum total bilirubin >3 × ULN as assessed by local laboratory
8. Previous registration in this study.
9. Current enrollment or a plan to enroll in any interventional clinical study in which an investigational treatment or approved therapy for investigational use is administered within 30 days (or 5 half-lives of the agent, whichever is longer) prior to the Baseline Visit.
10. Inability to comply with study requirements.
11. Presence of any medical or psychological condition or laboratory result that in the opinion of the Investigator can interfere with the subject's ability to comply with the protocol requirements or makes the subject not appropriate for inclusion to the study and treatment with Elocta/Eloctate.
12. Other unspecified reasons that, in the opinion of the Investigator or Bioverativ, make the subject unsuitable for enrollment.
13. Unwillingness or inability to comply with the requirements of the protocol, including the presence of any condition (physical, mental, or social) that prevents the subject from participating in visits as scheduled
14. Concurrent systemic treatment with immunosuppressive drugs within 12 weeks prior to Screening. Exceptions to this include: ribavirin for treatment of hepatitis C virus (HCV), and/or systemic steroids (a total of 2 courses of pulse treatments lasting no more than 7 days within 12 weeks prior to Day 1) and/or inhaled steroids
The following criteria refer to tests performed within 26 weeks prior to Screening. If not available, a new test should be drawn at the Screening visit.
15. Cluster of differentiation 4 (CD4) lymphocytes >200 mm3 at Screening, if known as human immunodeficiency virus (HIV) antibody positive based on medical history or HIV testing
16. Viral load of <400 copies/mL at Screening, if known HIV antibody positive, based on medical history. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint of this study is time to tolerization with a maximum of 12 months ITI treatment offered in the study. (Tolerization defined as inhibitor titer <0.6BU/ml, FVIII recovery > 66% and t1/2 of ≥7hrs) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The primary endpoint of time to tolerization will be summarized descriptively using minimum, mean, standard deviation, median, 25th and 75th quartiles, and maximum. A Kaplan-Meier plot showing percentage of subjects who are tolerized against time from the first ITI infusion will also be generated. Subjects not achieving ITI success during the 12 months ITI period will be censored at the last observed time for this analysis. The ITIFAS analysis set will be used for this analysis |
|
E.5.2 | Secondary end point(s) |
•ITI success
oNegative titer for inhibitor (<0.6 BU/mL by the Nijmegen-modified Bethesda assay) in 2 consecutive determinations
oFVIII incremental recovery (IR) >1.3 IU/dL per IU/kg in 2 consecutive determinations representing 66% of the expected IR 2 IU/dL per IU/kg (ref SmPC).
oFVIII t1/2 ≥7 hours
•Occurrence of relapse during a 48-week period following successful ITI treatment (defined as inhibitor titer >0.6 BU/mL or abnormal recovery after tolerance is achieved)
•Number of bleeding episodes during ITI and during the 48-week period after successful ITI performed with rFVIIIFc
•Treatment emergent adverse events (TEAE) and treatment emergent serious adverse events (TESAE)
•Number of days away from work or school
•Number of hospitalization days
•Adherence (defined as percentage of administered doses versus planned doses)
•Consumption of rFVIIIFc (measured in total rFVIIIFc use)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
After Baseline Visit which is the start of ITI treatment, subjects will be seen at Week 2 and every fourth week until subjects acheive a negative inhibitor titer (<0.6 BU/mL). Starting at time of first negative inhibitor titer until ITI success OR 48 weeks of treatment, subjects will be seen every 2nd week. With ITI success (3 success criteria met) and continuing for 16 weeks (Tapering period), subjects will have assessment visits after 2 weeks, 4 weeks and then every 4th week thereafter. Follow-up Period constitutes the time period in which subject returns to prophylactic dosing regimen and will be approximately 32 weeks in duration. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 12 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
Canada |
European Union |
France |
Germany |
Italy |
Japan |
Puerto Rico |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of study is last subject, last visit for final collection of data. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |